TNFSF13 and Miyoshi myopathy: Due to their impressive safety profile and significant APRIL-lowing effect by BION-1301, the first humanized MoAb against APRIL, in the Phase 1 and 2 study, a rationale was provided for further combination therapy with BCMA-based immunotherapy or other anti-MM agents [108].